The Clinical Potential of Targeted Nanomedicine: Delivering to Cancer Stem-like Cells

Citations Over TimeTop 10% of 2013 papers

Abstract

Cancer stem-like cells (CSCs) have been implicated in recurrence and treatment resistance in many human cancers. Thus, a CSC-targeted drug delivery strategy to eliminate CSCs is a desirable approach for developing a more effective anticancer therapy. We have developed a tumor-targeting nanodelivery platform (scL) for systemic administration of molecular medicines. Following treatment with the scL nanocomplex carrying various payloads, we have observed exquisite tumor-targeting specificity and significant antitumor response with long-term survival benefit in numerous animal models. We hypothesized that this observed efficacy might be attributed, at least in part, to elimination of CSCs. Here, we demonstrate the ability of scL to target both CSCs and differentiated nonstem cancer cells (non-CSCs) in various mouse models including subcutaneous and intracranial xenografts, syngeneic, and chemically induced tumors. We also show that systemic administration of scL carrying the wtp53 gene was able to induce tumor growth inhibition and the death of both CSCs and non-CSCs in subcutaneous colorectal cancer xenografts suggesting that this could be an effective method to reduce cancer recurrence and treatment resistance. This scL nanocomplex is being evaluated in a number of clinical trials where it has been shown to be well tolerated with indications of anticancer activity.

Related Papers

• → Cancer nanomedicine: is targeting our target?(2016)227 cited
• → Image-Guided Cancer Nanomedicine(2018)31 cited
• → Tabletized Nanomedicine: From the Current Scenario to Developing Future Medicine(2024)9 cited
• → Nanomedicine: Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines (Adv. Healthcare Mater. 1/2018)(2018)7 cited
• → NANOMEDICINE—PRESENT AND FUTURE OF DISEASE MANAGEMENT(2022)